On Sept. 13, 2020, Gilead Sciences and Immunomedics announced an agreement whereby Gilead would acquire Immunomedics for $88.00 per share in cash.

The transaction, which valued Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and was anticipated to close during the fourth quarter of 2020.